What does a VNS responder rate mean?
Read the published outcomes for children and adolescents. Compare seizure reduction, seizure freedom and what different study designs can tell us.
Enlarge for bigger labels, then swipe sideways →
The pooled responder estimate is 56.4% (95% CI 52.4–60.4). It is not a prediction for a teenager or a treatment decision.
What this model assumes
Published proportions are displayed, not recalculated or combined. Icons round to the nearest percentage point and do not represent individual patients. Pooled responder and seizure-freedom estimates may come from different subsets of studies; the smaller estimate is shown separately, not as observed members of the same cohort. Confidence intervals describe uncertainty in the pooled estimate, not a personal outcome range. Cohort percentages concern the predominant seizure type at different follow-ups. The randomized comparison used two active stimulation levels; the total sample was 41, not 100 in each arm. Outcomes not extracted from the selected source are unavailable, not zero. Studies include children and adolescents, not a teen-only group. This page provides no stimulation settings, treatment recommendation or individual prediction. Decisions belong with the family and child neurologist.
A responder can still have seizures.
This is an evidence-reading lesson, not medical advice or a decision tool. VNS uses an implanted generator and a lead to stimulate the vagus nerve. The US label covers adjunctive treatment for people aged four and older with partial-onset seizures refractory to antiepileptic medication. Treatment decisions belong with a child neurologist and the family.
The 2021 meta-analysis included 101 studies of patients aged 18 or younger. At last follow-up (mean 2.54 years), the pooled responder estimate was 56.4% (95% CI 52.4–60.4), while seizure freedom was 11.6% (9.6–13.9). These separate pooled estimates do not identify the same individual patients. The studies do not provide a teen-only prediction.
The retrospective 347-child cohort reported responder rates for the predominant seizure type of 32.5%, 37.6% and 43.8% at 6, 12 and 24 months. Follow-up and outcome definitions matter when comparing studies.
The 41-child randomized trial compared higher and lower active stimulation. During its 20-week blinded phase, 16% and 21% responded (p = 1.00). No clear difference was detected; a small, inconclusive comparison does not prove that the treatments are equivalent.
Observational improvement alone cannot isolate the effect of VNS from other changes. Relevant risks include voice changes, cough, breathing difficulty and surgical infection. This page omits device settings and does not provide a complete risk assessment.
Does a 56% responder rate mean 56 of 100 teenagers become seizure free?
Taking a real process
beyond the lab?
Jon and I are building RARE Labs toward an autonomous pilot plant builder using AI and robotics. Join the waitlist for updates, and tell us what you’re trying to scale.
Go a little deeper.
- Jain & Arya, Neurology (2021)Pediatric VNS systematic review and meta-analysis ↗
101 studies; pooled outcomes, intervals and follow-up. Abstract verified via Europe PMC November 7, 2026.
- Orosz et al., Epilepsia (2014)European retrospective cohort of 347 children ↗
Predominant-seizure responder rates at 6, 12 and 24 months.
- Klinkenberg et al. (2012)Randomized active-controlled pediatric trial ↗
41 children; 16% versus 21% in the blinded phase. Abstract verified via Europe PMC November 7, 2026.
- LivaNova, US prescribing safety summary (April 2025)Indication and safety information ↗
Manufacturer label: adjunctive use, age four and older, refractory partial-onset seizures; safety warnings. Read November 7, 2026.